Schizophrenia and Disorders with Psychotic Features  >>  Vraylar (cariprazine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
NCT01104779: Safety and Efficacy of Cariprazine in Schizophrenia

Completed
3
446
US, RoW
Cariprazine, RGH-188, Placebo
Forest Laboratories, Gedeon Richter Ltd.
Schizophrenia
12/11
12/11
NCT01104766: Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Checkmark ACNP 2015
Dec 2015 - Dec 2015: ACNP 2015
Completed
3
617
US, Europe, RoW
Cariprazine, RGH-188, Aripiprazole, Placebo
Forest Laboratories, Gedeon Richter Ltd.
Schizophrenia
12/11
12/11
NCT01412060 / 2011-002048-29: A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Checkmark SIRS 2016
Mar 2016 - Mar 2016: SIRS 2016
Checkmark ACNP 2015
Dec 2015 - Dec 2015: ACNP 2015
Completed
3
765
US, Europe, RoW
Placebo, Cariprazine, RGH-188
Forest Laboratories, Gedeon Richter Ltd.
Schizophrenia
09/14
09/14

Download Options